U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06833164) titled 'ERAP1,2 in Recalcitrant Warts' on Feb. 13.
Brief Summary: The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.
Study Start Date: Oct. 01, 2022
S...